Tab%25252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors for being primarily excreted via the enterohepatic system rather than the kidneys. ## Primary Indications Adjunctive therapy to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. ## Adult Dosing 5 mg orally once daily. May be taken with or without food. ## Pediatric Dosing Safety and efficacy have not been established in pediatric patients (under 18 years). Use is not recommended. ## Dose Adjustments * **Renal Impairment:** No dose adjustment required. * **Hepatic Impairment:** No dose adjustment required. * **Geriatric:** No dose adjustment required. ## Contraindications * History of hypersensitivity reaction to linagliptin (e.g., angioedema, urticaria, or bronchial hyperreactivity). * History of pancreatitis. ## Adverse Effects * **Common:** Nasopharyngitis, diarrhea, arthralgia. * **Serious:** Acute pancreatitis (discontinue immediately if suspected), bullous pemphigoid (may require topical or systemic immunosuppressive therapy), severe hypersensitivity reactions, potential for severe joint pain. ## Key Drug Interactions * **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin efficacy. If combined, monitor glycemic control closely as dose may need adjustment or therapy may require switching to a non-CYP3A4-metabolized agent. * **Insulin/Secretagogues:** May increase the risk of hypoglycemia; a reduction in the dose of the insulin or secretagogue may be required. ## Monitoring * **HbA1c:** Typically every 3–6 months. * **Pancreatitis:** Monitor for persistent, severe abdominal pain. * **Skin:** Monitor for blistering or erosions suggestive of bullous pemphigoid. * **Renal Function:** While dose adjustment is not required, monitoring is standard practice in diabetic care. ## Clinical Pearls * **Renal Sparing:** Linagliptin is the only oral DPP-4 inhibitor that does not require dose adjustment for renal impairment. * **Weight Neutral:** Linagliptin is weight neutral and has a low risk of hypoglycemia when used as monotherapy. * **Not for Type 1 DM:** Should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and prescribing information can change. Always verify current, site-specific prescribing information, contraindications, and drug interactions via local formulary databases or the official FDA-approved package insert before prescribing or administering medication.